Karolinska Development announces the formation of KDev Oncology AB - Carl Harald Janson appointed as CEO
(Thomson Reuters ONE) -
STOCKHOLM, SWEDEN - February 13, 2012. Today, Karolinska Development AB
announced the formation of a new, focused oncology group called KDev Oncology
AB, a fully owned subsidiary of Karolinska Development AB. KDev Oncology will
hold new oncology project companies, including the existing portfolio company
Akinion Pharmaceuticals AB. Carl Harald Janson has been appointed as CEO for
KDev Oncology.
Karolinska Development's ambition is to improve focus and efficiency in this
important therapeutic area by developing new oncology projects in the company
KDev Oncology. The formation of KDev Oncology enables Karolinska Development and
its co-investors to accumulate projects within a specific therapeutic area to
obtain synergies and critical mass. Starting with an existing company, Akinion
Pharmaceuticals, KDev Oncology will be able to include another four to five new
project companies within oncology.
Dr. Torbjörn Bjerke, CEO, Karolinska Development AB:
"We are very pleased to announce our increased focus and continued investment in
the oncology area. This is an important, strategic step for Karolinska
Development. We obtained significant synergies by collecting our dermatology
assets into Pergamum, and intend to start using this model for all new projects
where we see that we can improve the efficiency of the invested capital. It is
our strong belief that this will not only help recruit top competence within
oncology and attract new pharmaceutical projects, but also that it will attract
co-investments and support exits when projects are successful."
Carl Harald Janson has been appointed as CEO of KDev Oncology AB. He has served
as Investment Manager at Karolinska Development from 2008 to 2011 and is
currently a Board Director of four of Karolinska Development's portfolio
companies: Axelar, Oncopeptides, Clanotech and Akinion Pharmaceuticals. Carl
Harald holds an MD and a PhD from Karolinska Institutet and is a Certified
European Financial Analyst from the Stockholm School of Economics.
Dr. Terje Kalland, Chairman of the Board, KDev Oncology AB, and CSO, Karolinska
Development AB:
"KDev Oncology is the second therapeutic area group we have created and we aim
to do the same for other areas as well. These new groups will allow for
strengthened scientific development and cooperation, critical mass and efficient
use of resources. Therapeutic area groups will primarily include new projects,
and existing Karolinska Development project companies only where doing so
supports the efficiency of the group, as in this case in oncology. We welcome
Carl Harald Janson as the new CEO of KDev Oncology. Carl Harald's broad
experience across pharmaceutical development, investments and medicine will be
of great value in forming our future portfolio of oncology investments."
For further information, please contact:
Torbjörn Bjerke, CEO Karolinska Development AB
Phone: +46 (0) 72 744 41 23, e-mail: torbjorn.bjerke(at)karolinskadevelopment.com
Terje Kalland, Chairman of the Board, KDev Oncology AB
Phone: +46 (0) 76 891 73 01, e-mail: terje.kalland(at)karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class science into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP innovations
to the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out-licensing of
products. An exclusive deal flow agreement with Karolinska Institutet
Innovations AB, along with other cooperation agreements with leading Nordic
universities, delivers a continuous flow of innovations. Today, the portfolio
consists of 34 projects, of which 14 are in clinical development. For more
information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be
required to disclose the information provided herein pursuant to the Securities
Markets Act.
Press Release as PDF:
http://hugin.info/143071/R/1584841/495942.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1584841]
Unternehmensinformation / Kurzprofil:
Datum: 13.02.2012 - 08:02 Uhr
Sprache: Deutsch
News-ID 113616
Anzahl Zeichen: 5284
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 132 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development announces the formation of KDev Oncology AB - Carl Harald Janson appointed as CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
